Anti-Spike-RBD-fully-human-mAb(IgG) |
E24AHA001 |
EnoGene |
Human,-Human-IgG1.Affinity:(mol)4.15*10-10(Fortebio),-1.07-nM(ELISA).-FACs-Blocking:-0.892-nM- |
EUR 416.5 |
Description: Human, Human IgG1.Affinity: (mol) 4.15*10-10 (Fortebio), 1.07 nM (ELISA) . FACs Blocking: 0.892 nM |
Human IgG antibody Laboratories manufactures the spike rbd sequence reagents distributed by Genprice. The Spike Rbd Sequence reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike RBD. Other Spike products are available in stock. Specificity: Spike Category: Rbd Group: Sequence
Anti-SARS-CoV-2 Antibody IgG Quantitative and Titer Detection Kit (Spike RBD) |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective Assay kit detecting the levels of anti-SARS-CoV-2 in human serum can facilitate research on characterization of antibodies produced in response to SARS-CoV-2 infection. |
SARS-CoV-2 - RBD ELISA IgG |
ImmunoStep |
1 |
EUR 572 |
Description: SARS-CoV-2 - RBD ELISA IgG |
Rabbit monoclonal Anti-MERS Spike protein (S1/RBD/MERS-RBD) IgG (Neutralizing) |
Alpha Diagnostics |
100 ul |
EUR 781.2 |
JBS True Blue |
MiTeGen |
300 µl |
EUR 16 |
Description: JBS True Blue |
Sequence information
SARS-CoV-2 Spike RBD Titer Assay Kit |
RAS-A021 |
ACROBIOSYSTEMS |
96tests |
EUR 631.3 |
|
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 Spike RBD (N501Y) Rabbit mAb |
A21254 |
Abclonal |
20μL |
EUR 778.7 |
|
Description: A synthetic peptide corresponding to a sequence within amino acids 1-100 of human SR-B2/SR-B2/LIMPII (Q14108). |
SARS-CoV-2 Spike RBD Antibody Pair 1 |
55R-2273 |
Fitzgerald |
1 set |
EUR 833 |
|
Description: SARS-CoV-2 Spike RBD Antibody Pair 1 |
SARS-CoV-2 Spike RBD Protein ELISA Kit |
RK04135 |
Abclonal |
96T |
EUR 280 |
Spike-RBD-antigen-Fc |
E24PNA003 |
EnoGene |
2019-nCoV-Recombinant-Protein-Antigen,-SARS-CoV-2-Spike-RBD-Protein(Fc-Tag) |
EUR 416.5 |
Description: 2019-nCoV Recombinant Protein Antigen, SARS-CoV-2 Spike RBD Protein (Fc Tag) |
Spike-RBD-antigen-His |
E24PNA004 |
EnoGene |
2019-nCoV-Recombinant-Protein-Antigen,-SARS-CoV-2-Spike-RBD-Protein(His-Tag) |
EUR 416.5 |
Description: 2019-nCoV Recombinant Protein Antigen, SARS-CoV-2 Spike RBD Protein (His Tag) |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1 |
Jotbody |
each |
Ask for price |
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1-100 |
Jotbody |
100 |
EUR 148.12 |
Description: Primary VHH single domain antibody |
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1-1000 |
Jotbody |
1000 |
EUR 880.6 |
Description: Primary VHH single domain antibody |
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1-2000 |
Jotbody |
2000 |
EUR 1565.2 |
Description: Primary VHH single domain antibody |
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1-250 |
Jotbody |
250 |
EUR 246.17 |
Description: Primary VHH single domain antibody |
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1-50 |
Jotbody |
50 |
EUR 89.54 |
Description: Primary VHH single domain antibody |
SARS-CoV-2 Spike RBD (BA.2.12.1) ELISA Kit |
RAS-A130 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike RBD-coupled Magnetic Beads |
MBS-K002 |
ACROBIOSYSTEMS |
2mg |
EUR 2707.1 |
|
Description: SARS-CoV-2 Spike RBD protein is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Phe 541(Accession # QHD43416.1). |
Spike S1 RBD, Avi-His-tag (SARS-CoV-2) |
100696-1 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa. |